Author:
Lin Shi-Ming,Lu Sheng-Nan,Chen Ping-Tsung,Jeng Long-Bin,Chen Shinn-Cherng,Hu Chi-Tan,Yang Sien-Sing,Le Berre Marie-Aude,Liu Xuan,Mitchell David Y.,Prins Klaas,Grevel Joachim,Peña Carol A. E.,Meinhardt Gerold
Funder
Bayer HealthCare Pharmaceuticals
Onyx Pharmaceuticals, an Amgen subsidiary
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. The GLOBOCAN project. Lyon, France: International Agency for Research on Cancer, 2010. Available at: http://globocan.iarc.fr . Accessed 4 Nov 2015
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108
3. Hussain SA, Ferry DR, El-Gazzaz G, et al. Hepatocellular carcinoma. Ann Oncol. 2001;12(2):161–172
4. Katherine A, Hashem B. Global incidence of hepatocellular carcinoma. In: Bruix J, editor. Hepatocellular carcinoma. Barcelona: Permanyer; 2004
5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献